Publications Categories All categoriesNewslettersPodcastsPosition & Policy PapersReportsStatementsConsultation ResponsesNews ReleaseOpinion Topic Topic TopicAll TopicsAccess to MedicinesAgriculture & FoodAlcoholAntimicrobial Resistance (AMR)CancerChild HealthClean Air, Transport & CitiesClean Cooking & HeatingClimate CrisisDigital HealthDiscriminationEPHA NewsEurope and HealthHealth WorkforceHuman RightsMental HealthNon Communicable Diseases (NCDs)ObesityPandemics & Infectious DiseasesPartnershipsRoma HealthSocial Determinants of HealthSustainabilityTobaccoTrade & HealthUniversal Health Coverage Policy Policy PolicyAll PoliciesHealthy EnvironmentsHealthcare DeliveryHealth EquityHealth Systems and EconomyGlobal Public HealthDigital TransformationPolitics and Health Search Search Search Clear August 31, 2023Why you should care about Substances of Human Origin (SoHO)?In a world and time when health and healthcare are mainly approached from a commercial...OpinionHealth Systems and EconomyHealthcare DeliveryAccess to MedicinesJune 26, 2023Improving the transparency of clinical trials in the EUOn 22 and 23 June 2023, EPHA attended the kick-off workshop of the multistakeholder platform...ReportsHealthcare DeliveryEurope and HealthJune 1, 2023EPHA Newsletter | Exploring elements of the EU’s pharmaceutical legislationDeveloped in 1965, the first EU pharmaceutical legislation was a response to the tragic consequences...NewslettersHealthcare DeliveryAccess to MedicinesMay 31, 2023Will transparency of R&D costs lead to more affordable medicines?Without clear knowledge of pharmaceutical R&D costs, it is virtually impossible for regulators to design...OpinionHealthcare DeliveryAccess to MedicinesMay 31, 2023What could change in the fight against medicine shortages in Europe?With the COVID-19 pandemic and the multiplication of antibiotic supply disruptions, the fight against medicine...OpinionHealthcare DeliveryAccess to MedicinesMay 31, 2023Academic development of medicines – a path to solving unmet medical needsBy Dr Ward Rommel, Chair, Access to Medicines Task Force of Association of European Cancer...OpinionHealthcare DeliveryAccess to MedicinesApril 26, 2023Revising the EU pharmaceutical legislation and putting People before (Pharma) ProfitsEPHA welcomes the European Commission’s proposal and calls for a balanced debate so that the...News ReleaseHealthcare DeliveryPolitics and HealthAccess to MedicinesApril 12, 2023Why should one care about the new EU pharma law?Have you ever been to the pharmacy and couldn’t find the medicine you were looking...PodcastsHealthcare DeliveryPolitics and HealthAccess to MedicinesMarch 9, 2023CSOs call on the European Commission to publish revised EU pharmaceutical legislation no later than in March 2023Brussels, 9 March 2023 Dear Commissioner Kyriakides, We, the signatory organisations representing civil society, patients,...StatementsHealthcare DeliveryAccess to MedicinesMarch 7, 2023EPF and EPHA met with Commissioners Schinas and Kyriakides to discuss the ongoing pharmaceutical legislation revision and medicine shortagesBrussels, 7 March 2023 Yesterday afternoon, the European Public Health Alliance (EPHA) and the European...News ReleaseHealthcare DeliveryAccess to MedicinesFebruary 28, 2023EPHA’s contribution to the WHO Europe Access to Novel Medicines PlatformEPHA participated in an online consultation and submitted comments to the WHO Europe on their...Consultation ResponsesHealthcare DeliveryAccess to MedicinesFebruary 10, 2023Transferable exclusivity voucher: a flawed incentive to stimulate antibiotic innovationThe transferable exclusivity voucher is a costly, complex and untested incentive for new antibiotics. It...Position & Policy PapersHealthcare DeliveryAccess to MedicinesJanuary 25, 2023Joint letter | The shortage of antibiotics should be considered a “major event”To the EMA Executive DirectorTo the members of the Executive Steering Group on Shortages and...StatementsHealthcare DeliveryAccess to MedicinesJanuary 11, 2023Untapped Potential: Integrating Patient Perspectives for Inclusive Health Care Decision-MakingOECD’s Patient-Reported Indicator Surveys (PaRIS) initiative aims to measure outcomes and experiences of healthcare as...Position & Policy PapersHealthcare DeliveryPolitics and HealthDecember 15, 2022The need for more balance, transparency, and accountability in the pharmaceutical sectorWhile the COVID-19 pandemic has brought access and affordability of medicines to the spotlight, it...ReportsHealthcare DeliveryAccess to MedicinesDecember 8, 2022Recommendations for how HERA could ensure equitable pandemic preparedness and responseThe European Health Emergency Preparedness and Response Authority (HERA) recently celebrated its first anniversary. This paper...Position & Policy PapersHealthcare DeliveryEurope and HealthPandemics & Infectious DiseasesOctober 28, 2022Towards sustainable access to healthcare: patient-centred, needs-driven, and evidence-basedAccess is at the crossroad of innovation, strong evidence, affordable prices and societal needs.OpinionHealthcare DeliveryAccess to MedicinesOctober 28, 2022How the Pandemic Accord can ensure equitable access to medical productsA great opportunity to promote equitable access through increased transparency, IP reform, and technology transfer.OpinionHealthcare DeliveryAccess to MedicinesPandemics & Infectious Diseases Load more Get the EPHA Newsletter SUBSCRIBE
August 31, 2023Why you should care about Substances of Human Origin (SoHO)?In a world and time when health and healthcare are mainly approached from a commercial...OpinionHealth Systems and EconomyHealthcare DeliveryAccess to Medicines
June 26, 2023Improving the transparency of clinical trials in the EUOn 22 and 23 June 2023, EPHA attended the kick-off workshop of the multistakeholder platform...ReportsHealthcare DeliveryEurope and Health
June 1, 2023EPHA Newsletter | Exploring elements of the EU’s pharmaceutical legislationDeveloped in 1965, the first EU pharmaceutical legislation was a response to the tragic consequences...NewslettersHealthcare DeliveryAccess to Medicines
May 31, 2023Will transparency of R&D costs lead to more affordable medicines?Without clear knowledge of pharmaceutical R&D costs, it is virtually impossible for regulators to design...OpinionHealthcare DeliveryAccess to Medicines
May 31, 2023What could change in the fight against medicine shortages in Europe?With the COVID-19 pandemic and the multiplication of antibiotic supply disruptions, the fight against medicine...OpinionHealthcare DeliveryAccess to Medicines
May 31, 2023Academic development of medicines – a path to solving unmet medical needsBy Dr Ward Rommel, Chair, Access to Medicines Task Force of Association of European Cancer...OpinionHealthcare DeliveryAccess to Medicines
April 26, 2023Revising the EU pharmaceutical legislation and putting People before (Pharma) ProfitsEPHA welcomes the European Commission’s proposal and calls for a balanced debate so that the...News ReleaseHealthcare DeliveryPolitics and HealthAccess to Medicines
April 12, 2023Why should one care about the new EU pharma law?Have you ever been to the pharmacy and couldn’t find the medicine you were looking...PodcastsHealthcare DeliveryPolitics and HealthAccess to Medicines
March 9, 2023CSOs call on the European Commission to publish revised EU pharmaceutical legislation no later than in March 2023Brussels, 9 March 2023 Dear Commissioner Kyriakides, We, the signatory organisations representing civil society, patients,...StatementsHealthcare DeliveryAccess to Medicines
March 7, 2023EPF and EPHA met with Commissioners Schinas and Kyriakides to discuss the ongoing pharmaceutical legislation revision and medicine shortagesBrussels, 7 March 2023 Yesterday afternoon, the European Public Health Alliance (EPHA) and the European...News ReleaseHealthcare DeliveryAccess to Medicines
February 28, 2023EPHA’s contribution to the WHO Europe Access to Novel Medicines PlatformEPHA participated in an online consultation and submitted comments to the WHO Europe on their...Consultation ResponsesHealthcare DeliveryAccess to Medicines
February 10, 2023Transferable exclusivity voucher: a flawed incentive to stimulate antibiotic innovationThe transferable exclusivity voucher is a costly, complex and untested incentive for new antibiotics. It...Position & Policy PapersHealthcare DeliveryAccess to Medicines
January 25, 2023Joint letter | The shortage of antibiotics should be considered a “major event”To the EMA Executive DirectorTo the members of the Executive Steering Group on Shortages and...StatementsHealthcare DeliveryAccess to Medicines
January 11, 2023Untapped Potential: Integrating Patient Perspectives for Inclusive Health Care Decision-MakingOECD’s Patient-Reported Indicator Surveys (PaRIS) initiative aims to measure outcomes and experiences of healthcare as...Position & Policy PapersHealthcare DeliveryPolitics and Health
December 15, 2022The need for more balance, transparency, and accountability in the pharmaceutical sectorWhile the COVID-19 pandemic has brought access and affordability of medicines to the spotlight, it...ReportsHealthcare DeliveryAccess to Medicines
December 8, 2022Recommendations for how HERA could ensure equitable pandemic preparedness and responseThe European Health Emergency Preparedness and Response Authority (HERA) recently celebrated its first anniversary. This paper...Position & Policy PapersHealthcare DeliveryEurope and HealthPandemics & Infectious Diseases
October 28, 2022Towards sustainable access to healthcare: patient-centred, needs-driven, and evidence-basedAccess is at the crossroad of innovation, strong evidence, affordable prices and societal needs.OpinionHealthcare DeliveryAccess to Medicines
October 28, 2022How the Pandemic Accord can ensure equitable access to medical productsA great opportunity to promote equitable access through increased transparency, IP reform, and technology transfer.OpinionHealthcare DeliveryAccess to MedicinesPandemics & Infectious Diseases
